Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $568.5 million.

  • Axsome Therapeutics' Liabilities and Shareholders Equity rose 19.20% to $669.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 10.28%. This contributed to the annual value of $568.5 million for FY2024, which is 3.36% down from last year.
  • Axsome Therapeutics' Liabilities and Shareholders Equity amounted to $568.5 million in FY2024, which was down 3.36% from $588.2 million recorded in FY2023.
  • Over the past 5 years, Axsome Therapeutics' Liabilities and Shareholders Equity peaked at $588.2 million during FY2023, and registered a low of $331.5 million during FY2022.
  • For the 3-year period, Axsome Therapeutics' Liabilities and Shareholders Equity averaged around $496.1 million, with its median value being $568.5 million (2024).
  • Per our database at Business Quant, Axsome Therapeutics' Liabilities and Shareholders Equity skyrocketed by 77.46% in 2023 and then dropped by 3.36% in 2024.
  • Yearly analysis of 3 years shows Axsome Therapeutics' Liabilities and Shareholders Equity stood at $331.5 million in 2022, then surged by 77.46% to $588.2 million in 2023, then decreased by 3.36% to $568.5 million in 2024.